| Document |
Document Title |
|
JP2006257095A |
To provide a synthetic immunogenic polypeptide complex which can exhibit two different type antigens with a preliminarily defined accurate stoichiometry and molecular arrangement.A heterodimer polypeptide immunogen comprises a carrier ha...
|
|
JP2006520741A |
Modified active agent derivatives (I) containing an amino acid residue or peptide chain, a fluorinated hydrocarbon chain and a recognition or hydrophilizing moiety in addition to the parent active agent residue are new. Modified active a...
|
|
JP3816522B2 |
A pharmaceutical composition for stimulating the haematopoietic function and preventing the myelotoxic side-effects of some treatments, containing at least one water-soluble muramyl peptide derivative such as Muradimetide, muroctasine or...
|
|
JP2006219503A |
To provide a truncated HCV (Hepatitis C Virus) envelope protein useful for immunoassay and therapeutic/preventive vaccines.The HCV truncated glycoprotein is selected from a group consisting of glycoproteins expressed in HCV E1 domain and...
|
|
JP2006518759A |
It is taught here that enkephalin peptides which are glycosylated with a disaccharide will be transported across the blood brain barrier and deliver analgesic effects superior to morphine when introduced into the bloodstream. Glycosylate...
|
|
JP3801133B2 |
It is intended to provide an antibody specific to HbA1c, antibody-producing cells capable of supplying the antibody in a stable state in the future, and a method of constructing the antibody-producing cells without any probability factor...
|
|
JP2006180882A |
To provide a recombination method and recombinant substance for making ramoplanin by recombinant DNA technology, relating to a gene involved in ramoplanin biosynthesis.A specific contiguous DNA sequence comprises an ORF encoding a protei...
|
|
JP2006182785A |
To provide a pharmaceutical composition capable of mobilizing a large amount of stem cells derived from the bone marrow and forming the stem cells in the blood flow by stimulating hematopoietic function.The pharmaceutical composition con...
|
|
JPWO2004076476A1 |
The present invention provides a method for searching for a novel substance that can be used as an initiator of proteoglycan, and for efficiently synthesizing a substance that can be used as such an initiator. The present invention has t...
|
|
JP2006513273A |
The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.
|
|
JP2006513143A |
The invention relates to phosphopeptides inhibiting protein tyrosine phosphatases, and their uses.
|
|
JP3756539B2 |
PURPOSE: To provide the subject novel derivative as a specific glycopeptide antibiotic derivative having antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates, useful for an a...
|
|
JP2006063055A |
To provide a compound useful as a starting material for constructing a sugar peptide library.The compound is represented by formula (I) (wherein, P is a peptide chain having 1-20 amino acid residues wherein the sugar residue forms an O-g...
|
|
JP2006507233A |
The present invention provides novel glycosides and glycoconjugates, glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis t...
|
|
JP2006028141A |
To provide a method for rapidly producing a glycopeptide in a high yield.In the method for producing the glycopeptide by using a saccharide amino acid, a peptide bond-forming reaction is carried out while microwaves are irradiated thereto.
|
|
JP3741495B2 |
To obtain a novel conjugated glycopeptide resistant to disintegration in blood and useful as a therapeutic agent for AIDS infection by adding N- acetylglucosamine (GlcNAc) to the Asn residue in an octapeptide called peptide- T having ant...
|
|
JP2006503015A |
Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided...
|
|
JP2006500001A |
The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease.
|
|
JP2001513573A5 |
|
|
JP2005535280A |
This invention provides methods for modifying glycosylation patterns of glycoproteins, including recombinantly produced glycoproteins. Also provided are glycoprotein compositions in which the glycoproteins have a homogeneous glycosylatio...
|
|
JP2005529852A |
The invention regards a process for the production of ramoplanin-like derivatives of formula (I): RAMO-NC-CO-R (I), wherein the radical R represents a hydrocarbon radical and the portion RAMO-NH- represents deacylated ramoplanin, any of ...
|
|
JP2005529838A |
A process is described for preparing a substrate for the transglycosylase enzymes of bacterial cell wall biosynthesis. The chemical synthesis makes available a sustainable and substantially pure source of supply of lipid II, including an...
|
|
JP3691096B2 |
PURPOSE: To obtain the subject derivative for biological functional materials, etc., by amide bonding of α-amino group of L-lysin residue of a part or all of a poly(ε-L-lysin) with D-galactopyranosylgluconic acid, having good cell adhe...
|
|
JP2005523264A |
The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP alpha ), said prodrug is chemically stable under physiological conditions and can be us...
|
|
JP2005187479A |
To provide truncated HCV (Hepatitis C Virus) envelope proteins useful for an immunoassay and a therapeutic/prophylactic vaccine.The HCV truncated glycoprotein is selected from a group consisting of a glycoprotein which is expressed from ...
|
|
JP3651921B2 |
PURPOSE: To obtain an inhibitor for mastocyte free from a side effect and having a considerable inhibitory effect on liberation of histamine, etc. CONSTITUTION: Melanoidin synthesized by a reaction between a reducing sugar and one of an ...
|
|
JP2005510229A |
This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a homogeneous glycosylatio...
|
|
JP3628689B2 |
PCT No. PCT/GB92/02137 Sec. 371 Date May 18, 1994 Sec. 102(e) Date May 18, 1994 PCT Filed Nov. 19, 1992 PCT Pub. No. WO93/10148 PCT Pub. Date May 27, 1993.Muramyl peptide compounds which: (a) are non-pyrogenic; and/or (b) ameliorate endo...
|
|
JP2005504087A |
A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4'-disubstituted nucleoside or a pharmaceutically acceptable salt ...
|
|
JP2004536027A |
A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalen...
|
|
JP2004535388A5 |
|
|
JP2004535388A |
Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The. complexes of the invention comprise a drug, at least one lipid species, option...
|
|
JP3590638B2 |
New N-alkyl and N-acyl derivatives of A82846A, A82846B, A82846C and PA-42867-A are provided. The new glycopeptide derivatives are useful for the treatment of susceptible bacterial infections, especially infections due to Gram-positive mi...
|
|
JP2004529065A |
The present invention provides a laspartomycin core peptide, a laspartomycin core peptide derivative, a antimicrobial laspartomycin derivative, a method for making laspartomycin core peptides, methods for making laspartomycin core peptid...
|
|
JP2004528268A |
The present invention provides a laspartomycin core peptide, a laspartomycin core peptide derivative, a antimicrobial laspartomycin derivative, a method for making laspartomycin core peptides, methods for making laspartomycin core peptid...
|
|
JP2004520317A |
The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and ...
|
|
JP3539739B2 |
PURPOSE: To provide the subject new muramyldipeptide derivative having a specified molecular structure, exhibiting an adjuvant effect and useful as a component constituting an influenza virus-like artificial membrane vaccine, i.e., a vir...
|
|
JP2004184282A |
To provide a HbAlc measuring method of which the operation is easy and the measuring time is short as compared with an enzyme immunoassay being an immunological measuring method for HbAlc.A dye labelled compound, which has the structure ...
|
|
JP2004517932A |
The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of formula (1) in which Z 1 and Z 2 are moieties derived from sugar. The invention also provides methods for preparing such comp...
|
|
JP3522798B2 |
PURPOSE: To obtain a saccharide-modified protein raised in liver accumulativeness and physiological activity by saccharide modification of a saccharide-modified protein, esp. a physiologically active protein using a simple, universal che...
|
|
JP2004510449A |
The present invention relates to isolated genetic sequences encoding nonribosomal peptide synthetase (NRPS) proteins which direct the biosynthesis of the antibiotic ramoplanin in microorganisms such as Actinoplanes sp. The isolated gene ...
|
|
JP3503066B2 |
PCT No. PCT/EP94/01154 Sec. 371 Date Dec. 26, 1995 Sec. 102(e) Date Dec. 26, 1995 PCT Filed Apr. 14, 1994 PCT Pub. No. WO94/26780 PCT Pub. Date Nov. 24, 1994Synthetic aglucodalbaheptides of formula (I) wherein W and Z, each independently...
|
|
JP2004501161A5 |
|
|
JP2004501087A |
The stereospecific synthesis of a glycopeptide using a triply orthogonal protection scheme is described, in particular, the synthesis of N-acetylglucosaminyl-beta-[1,4]-N-acetylmuramylmonopeptide and derivatives thereof. The glycopeptide...
|
|
JP2004501085A |
A process is described for preparing a substrate for the transglycosylase enzymes of bacterial cell wall biosynthesis. The chemical synthesis makes available a sustainable and substantially pure source of supply of lipid II, including an...
|
|
JP2003267996A |
To provide an N-acetylglucosamine-bound opioid peptide derivative expected to have improved stability to heat, pH and enzymic digestion, and possibility of passage or the like through blood-brain barrier.The N-acetylglucosamine (GlcNac)-...
|
|
JP2003527443A |
The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
|
|
JP2003525837A |
Randomly generated glycopeptide combinatorial libraries are generated by randomly glycosylating a peptide having at least one glycosylation site with at least one glycosyl donor, optionally blocking unreacted glycosylation sites on the g...
|
|
JP2003235590A |
To provide nucleic acid analogues for use in the capture, recognition, detection, identification, or quantification of one or more chemical or biological entities, and to provide methods for using the analogues in diagnostics and analyti...
|
|
JP2003522197A |
The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.
|
